Psilocybin Therapy for Depression: What Clinical Trials Reveal
Psilocybin therapy for depression has moved from the fringes of psychiatry to the center of clinical research. Universities and drug developers are testing whether one or two supervised psilocybin sessions, combined with psychological support, can relieve depression in people who have not responded to conventional treatment.The results so far are encouraging but uneven. Some randomized trials show large improvements, one head-to-head trial found no clear advantage over a standard antidepressant, and the most advanced studies are still moving toward regulatory review. This article walks through what the trials actually found, how strong the evidence is, and where the real uncertainty lies.
What Is Psilocybin Therapy for Depression?
Psilocybin is a naturally occurring compound found in many species of mushrooms. After ingestion, the body converts it to psilocin, the molecule that produces the psychoactive effects. Psilocin binds to serotonin receptors throughout the brain, particularly the 5-HT2A receptor, and temporarily changes perception, mood, and thought patterns.
Researchers are still working out why this might help depression. Brain imaging studies suggest psilocybin alters communication between large-scale brain networks, including ones linked to rumination and self-focused thinking. Some researchers propose that this creates a window of increased emotional and cognitive flexibility, which therapy can then build on. These are working hypotheses, not settled mechanisms.
Psilocybin is not studied as a standalone pill. In trials, it is part of psilocybin-assisted psychotherapy:
- Preparation: Sessions with trained clinicians to build rapport and set expectations.
- Supervised dosing: A session of several hours in a calm, monitored setting.
- Integration: Follow-up sessions to process the experience.
The drug and the therapeutic framework are studied together, so results should not be applied to unsupervised use.
What Do Clinical Trials Reveal About Psilocybin for Depression?
The evidence base includes small open-label studies, randomized controlled trials (RCTs), and large industry-sponsored Phase 2b and Phase 3 programs. In broad terms:
- Symptom reduction: Several RCTs found larger drops in depression scores with psilocybin than with control conditions.
- Response and remission: Rates vary widely by study, population, and dose. In a Johns Hopkins trial, about 71% of participants responded and 54% were in remission four weeks after treatment. In a large trial of treatment-resistant depression, the benefit over a control dose was smaller but statistically significant.
- Duration: Improvement lasted weeks to months in many participants, and a 12-month follow-up of one study found sustained benefit in a large share of them. Some people relapse.
- Safety: Most adverse events were temporary and tied to dosing day, but some trials reported suicidal ideation or self-injury in some participants, so close monitoring is essential.
The next section looks at the key studies in detail.
Major Clinical Studies on Psilocybin and Depression
Johns Hopkins University: Davis et al. (2021)
- Question: Does psilocybin-assisted therapy reduce symptoms of major depressive disorder (MDD)?
- Design: Randomized, wait-list-controlled trial published in JAMA Psychiatry. Participants received two psilocybin sessions with supportive psychotherapy, either immediately or after an eight-week delay.
- Participants: 24 adults with moderate to severe MDD.
- Findings: Depression scores dropped sharply in the immediate-treatment group compared with the delayed group, with about 71% showing a response and 54% in remission at the four-week follow-up.
- Limitations: Small sample, no blinding (participants knew whether they were treated), and a wait-list comparison rather than a placebo. A later 12-month follow-up (Gukasyan et al., 2022) found that many participants maintained benefit, though follow-up without a control group is hard to interpret.
Imperial College London: Carhart-Harris et al. (2016 and 2021)
2016 open-label study (Lancet Psychiatry). Twelve people with treatment-resistant depression received psilocybin with psychological support. Symptoms improved markedly over the first weeks. With no control group, it was a feasibility and signal-finding study.
2021 randomized trial (New England Journal of Medicine).
- Question: How does psilocybin compare with a standard antidepressant, escitalopram?
- Design: Double-blind, randomized, six-week trial. One group received two 25 mg psilocybin doses three weeks apart plus six weeks of a placebo capsule. The other received two very low (1 mg) psilocybin doses plus six weeks of daily escitalopram. Both received psychological support.
- Participants: 59 adults with moderate to severe MDD.
- Findings: On the primary measure (QIDS-SR-16), the difference between groups was not statistically significant. Secondary measures, including remission (about 57% vs 28%), favored psilocybin, but those were not adjusted for multiple comparisons and should be treated as exploratory.
- Limitations: Small sample, short comparison period, and a design that makes blinding difficult.
COMPASS Pathways: Goodwin et al. (2022) and Phase 3 Trials
2022 Phase 2b trial (New England Journal of Medicine).
- Question: Does COMP360, a synthetic psilocybin formulation, help people with treatment-resistant depression, and at what dose?
- Design: Randomized, double-blind, dose-finding trial comparing 25 mg, 10 mg, and 1 mg single doses, with psychological support.
- Participants: 233 adults with treatment-resistant depression.
- Findings: At week 3, the 25 mg dose reduced depression scores by about 6.6 points more than the 1 mg dose. The 10 mg dose did not differ significantly from 1 mg. Adverse events were more common at higher doses, and suicidal ideation or self-injury occurred in some participants across groups.
- Limitations: Short primary endpoint, and a very low dose as the comparator may not have fully hidden group assignment.
Phase 3 program (2025–2026). According to the company and trade press, COMP005 (258 participants at 32 U.S. sites) met its primary endpoint, and COMP006 (about 580 participants) reported a positive result at week 6 and 26-week data in July 2026. The company reported about a 39% response rate after two doses in COMP006, versus about 25% after one dose in COMP005. These are sponsor-reported results announced ahead of peer-reviewed publication, so the full methods, effect sizes, and safety data should be reviewed once published.
Other Randomized Trials
- Raison et al. (2023, JAMA): A randomized, double-blind trial of 104 adults with MDD comparing a single 25 mg dose of psilocybin with niacin as an active placebo. Depression scores were significantly lower with psilocybin at day 43, by about 12 points on the MADRS. Limitations include a single-dose design and a short primary follow-up.
- von Rotz et al. (2023): A placebo-controlled, double-blind randomized trial in Switzerland with 52 participants with MDD, which also reported benefit from a single dose. Look up the full publication on PubMed to confirm methods and figures before citing.
Comparison Table of Key Trials
Study | Design | Participants | Condition | Main finding |
|---|---|---|---|---|
Carhart-Harris 2016 | Open-label | 12 | Treatment-resistant depression | Large early improvement; no control group |
Davis 2021 | Randomized, wait-list | 24 | MDD | ~71% response, ~54% remission at 4 weeks |
Carhart-Harris 2021 | Randomized, vs escitalopram | 59 | MDD | No significant difference on primary measure |
Goodwin 2022 | Phase 2b, double-blind, dose-finding | 233 | Treatment-resistant depression | 25 mg beat 1 mg at week 3 |
Raison 2023 | Randomized, double-blind, niacin control | 104 | MDD | Significant reduction at day 43 |
COMP005 / COMP006 | Phase 3 (sponsor-reported) | 258 / ~580 | Treatment-resistant depression | Primary endpoints reported met |
Summary of the Strongest Evidence
The strongest evidence is for short-term symptom reduction after one or two supervised sessions, supported by randomized, controlled trials of 100 or more participants. The weaker areas are long-term durability, superiority over existing antidepressants, and generalizability to the broader population of people with depression.
How Effective Is Psilocybin Therapy Compared With Traditional Antidepressants?
The two approaches differ in how they work in practice:
- Conventional antidepressants are usually taken daily for months or longer, and may take weeks to reach full effect.
- Psilocybin-assisted therapy in trials involves one or two intensive sessions, with effects reported within days to weeks, plus preparation and integration therapy.
Direct comparative evidence is limited to the Imperial College trial, which found no significant difference on its primary measure. A single, small trial is not enough to claim psilocybin is better, or worse, than antidepressants. Differences in treatment length, cost, supervision, and follow-up also make comparisons difficult. Anyone currently taking antidepressants should talk to their prescriber, because stopping suddenly can cause withdrawal symptoms and relapse.
Potential Benefits of Psilocybin Therapy for Depression
Based on current trial data, researchers have reported:
- Reduced depressive symptoms in a substantial share of participants, sometimes lasting months.
- Improved emotional well-being and sense of connection in some studies.
- Greater psychological flexibility, a measure of how adaptably people respond to difficult thoughts, reported in exploratory analyses.
- Possible improvements in quality of life, though this is less consistently measured.
- Sustained improvement in some participants, with a minority maintaining benefit at 6 to 12 months.
These are preliminary findings and not established clinical conclusions. Many measures were secondary or exploratory, and not every participant improved.
Risks and Side Effects of Psilocybin Therapy
Potential adverse effects reported in trials include:
- Anxiety and psychological distress during sessions, sometimes intense.
- Nausea and headache, often on the dosing day or the day after.
- Temporary increases in blood pressure and heart rate.
- Confusion and challenging psychological experiences, which supervised settings are designed to manage.
- Suicidal ideation or self-injury reported in some participants in some trials, the causes of which are still being studied.
- Risks for people with certain psychiatric conditions, particularly a personal or family history of psychosis or bipolar I disorder.
Trials manage these risks with medical screening, preparation, trained monitors, and follow-up. Unsupervised psychedelic use is not equivalent to clinical treatment. Doses of natural mushrooms vary, there is no screening, and no one is trained to respond to a crisis.
Who May Qualify for Psilocybin Clinical Trials?
Eligibility depends on the study, but typical inclusion criteria include:
- Adult age.
- A confirmed diagnosis of MDD or treatment-resistant depression by a structured clinical interview.
- For treatment-resistant trials, an inadequate response to one or more adequate antidepressant trials.
Common exclusion criteria include:
- Personal or family history of psychosis or bipolar I disorder.
- Certain medications, such as lithium or some serotonergic drugs.
- Pregnancy or breastfeeding.
- Serious or uncontrolled cardiovascular conditions.
- Active suicidal risk or significant substance use disorders, depending on the protocol.
Researchers screen carefully because the potential for harm is greater in some groups, and because trial results are only valid for the populations studied.
To find legitimate studies, search ClinicalTrials.gov for “psilocybin” and “depression,” and look for trials with a named sponsor, ethics approval, and a listed contact. Talk to your doctor or psychiatrist before applying, and never taper or stop prescribed medication on your own to join a study.
How Does Psilocybin-Assisted Therapy Work?
A typical research framework includes:
- Screening: Psychological and medical evaluation, including medication review.
- Preparation sessions: Meetings with therapists to discuss intentions, expectations, and what the session may feel like.
- Supervised administration: Psilocybin is given in a controlled setting, often with music and eye shades.
- Monitoring: Two trained facilitators stay with the participant, tracking safety and offering support.
- Integration and follow-up: Sessions to process the experience and monitor mood, with safety checks over the following weeks.
Protocols vary between studies in dose, number of sessions, amount of therapy, and monitoring approach, and they are not standardized across research programs.
Limitations of Current Psilocybin Depression Research
- Small sample sizes: Several important trials enrolled fewer than 100 people.
- Blinding difficulties: The psychedelic experience is hard to disguise, so participants often know which group they are in.
- Placebo and expectancy effects: Participants who join psychedelic studies may expect benefit, which can shape outcomes.
- Selection bias: Many participants have been previously interested in psychedelics, and trials have often lacked racial and socioeconomic diversity.
- Protocol differences: Differences in dose, support, and outcome measures make comparisons across trials harder.
- Limited long-term follow-up: Most data cover weeks to months, with less information about safety and durability beyond a year.
- Industry sponsorship: Some of the largest trials are sponsored by developers, and the latest results are not yet fully peer reviewed.
Larger, more diverse, independently run trials with longer follow-up are still needed.
What Is the Future of Psilocybin Therapy for Depression?
Several lines of research are ongoing:
- Ongoing and larger randomized trials, including peer-reviewed publication of Phase 3 data.
- Long-term safety studies, including repeat dosing and follow-up beyond a year.
- Treatment-resistant depression research, where the need is greatest.
- Better predictors of who benefits and who is at greater risk.
- Regulatory developments: As of the most recent reports, the sponsor of the COMP360 program has said it plans to complete its FDA submission in the fourth quarter of 2026. A submission does not guarantee approval, and any approval would also involve decisions on scheduling, risk management, and delivery. Plans and timelines can change.
It is too early to say whether, when, or how widely psilocybin therapy will become available as a standard treatment.
Frequently Asked Questions
Does psilocybin therapy work for depression?
In several randomized trials, psilocybin-assisted therapy reduced depression symptoms more than control conditions in some participants. However, one head-to-head trial found no significant advantage over escitalopram on its primary measure, and not everyone responds. The evidence is promising but still developing.
Can psilocybin help with treatment-resistant depression?
A 233-person Phase 2b trial found that a 25 mg dose reduced symptoms more than a 1 mg dose at three weeks in treatment-resistant depression. Sponsor-reported Phase 3 results are also positive, but they are not yet fully peer reviewed, and results vary between participants.
What do clinical trials say about psilocybin for depression?
Trials generally show short-term symptom reductions after one or two supervised sessions, with some benefits lasting months. They also show limits: small samples, blinding problems, and limited long-term data. No trial has shown that psilocybin is a guaranteed cure or clearly better than antidepressants.
How long do the antidepressant effects of psilocybin last?
In some trials, improvements lasted weeks to months, and a 12-month follow-up of one study found sustained benefit in many participants. Durability varies by person, and some relapse. Company-reported Phase 3 data describe response lasting around six months on average among responders.
Is psilocybin therapy better than traditional antidepressants?
There is no good evidence yet that it is better. The only major head-to-head trial found no significant difference on its primary measure. The treatments differ in schedule, supervision, and cost, so comparisons are difficult. Do not stop prescribed antidepressants without medical advice.
What are the risks of psilocybin therapy?
Common effects include anxiety, nausea, headache, and temporary rises in blood pressure and heart rate, mostly on dosing day. Some trial participants reported suicidal thoughts or self-injury. People with histories of psychosis or bipolar I disorder are usually excluded, and screening and supervision matter greatly.
How many psilocybin sessions are needed for depression?
It depends on the trial. Some studies used one dosing session, such as Raison 2023 and Goodwin 2022, while others used two, such as Davis 2021 and the Imperial College trial. Each included preparation and integration therapy. The optimal number of sessions has not been established.
Is psilocybin therapy legally available?
It depends on location. Psilocybin is a Schedule I substance under U.S. federal law, though Oregon and Colorado have created regulated programs and Australia allows specially authorized psychiatrists to prescribe it for certain conditions. Laws are changing, so check current local rules and speak with a clinician.
What is the difference between psilocybin and psilocin?
Psilocybin is the compound found in mushrooms. After it is swallowed, the body converts it to psilocin, the molecule that actually binds to serotonin receptors such as 5-HT2A and produces the psychedelic effects. In practice, psilocybin acts as a precursor, or prodrug, of psilocin.
Where can I find legitimate psilocybin clinical trials?
Search ClinicalTrials.gov for psilocybin and depression, and check that each study lists a named sponsor, ethics approval, eligibility criteria, and a contact. Discuss any interest with your doctor first, and avoid anyone offering treatment outside a registered or regulated program, or guaranteeing results.